The primary therapeutic domain for Кардосал 20 (Olmesartan Medoxomil) is applied in situations involving certain distressing symptoms related to systemic imbalance.

The medication is commonly used to treat High Blood Pressure (Essential Hypertension) in adults and children aged 6 years and older. The primary use is in managing symptoms related to persistent high arterial pressure, and is relevant in contexts involving heightened systemic burden. It is used in conditions marked by increased physiological stress, and it contributes to easing the overall symptom load related to vascular health.

This treatment is considered relevant for Comprehensive Cardiovascular Risk Reduction, specifically addresses symptoms associated with acute or episodic changes in vascular health. This action supports patients by easing the functional stress on organs like the brain, heart, and kidneys, which is applicable across domains where additional symptomatic support is needed.

---

Quick Fact: Support for Systemic Imbalance

The medication plays a role in managing the noticeable physiological strain associated with chronic essential hypertension, contributes to improving day-to-day comfort and assists with maintaining functional stability for patients, particularly in high-risk populations.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Кардосал 20 (Olmesartan Medoxomil)

The eligibility for Кардосал 20 is determined by official regulatory guidelines, defining approved populations and strict contraindications.

Populations Approved for Use

Age Group	Eligibility Status (Regulatory Label)
Adults	Approved for treatment of essential hypertension.
Children	Approved for those aged 6 years and older (who weigh 20 kg) for hypertension.
Geriatric Patients	No initial dosage adjustment is typically required.

Absolute Contraindications (Who Must Not Use)

Кардосал 20 is strictly prohibited in certain patient populations as defined by regulatory authorities:

• Pregnancy: It is contraindicated during the second and third trimesters. Use must be discontinued immediately upon detection of pregnancy.
• Infants: The medication is contraindicated for children younger than 1 year of age.
• Metabolic/Dual Therapy: It is contraindicated for patients with Diabetes Mellitus who are simultaneously receiving the drug Aliskiren.
• Hypersensitivity: Patients with a known allergy to Olmesartan Medoxomil or any component of the tablet must not use this medicine.

Restricted or Conditional Use

Use is generally not recommended or requires heightened caution and supervision in patients with severe hepatic impairment, severe renal impairment, and for breastfeeding/nursing mothers.

Interactions with other medicines and products

The interaction profile for Кардосал 20 (Candesartan Cilexetil) is primarily defined by its effects on blood pressure and electrolyte balance, necessitating careful monitoring when co-administered with specific drug classes.

Pharmacodynamic Interactions

Interaction Type	Interacting Agents	Resulting Constraint/Effect
Dual RAS Blockade	Aliskiren (in specific populations), ACE-inhibitors	Contraindicated with Aliskiren in patients with diabetes or moderate-to-severe renal impairment. Increased risk of hypotension and hyperkalaemia.
Hyperkalaemia Risk	Potassium-sparing diuretics, Potassium supplements, Heparin	Increased risk of hyperkalaemia (elevated serum potassium levels).
Antihypertensive Effect	Other antihypertensive agents	May enhance the blood pressure-lowering effect, increasing the risk of hypotension.
Effect Attenuation	NSAIDs (including COX-2 inhibitors)	Potential attenuation of the blood pressure-lowering effect; increased risk of worsening renal function.

Other Significant Interactions

Concomitant use with Lithium has been reported to cause reversible increases in serum lithium concentrations and toxicity, requiring close monitoring of serum lithium levels.

Candesartan is eliminated to a minor extent via the CYP2C9 hepatic enzyme system. However, tested pharmacokinetic studies have indicated that interactions via this metabolic pathway are generally not considered clinically significant, and no specific timing requirements are mandated relative to food intake or other medications.

How Кардосал 20 Works: Mechanism of Action

Кардосал 20 works by delivering olmesartan, a compound that selectively blocks the Angiotensin II Type 1 ( AT1) receptor. This action prevents the vasoconstrictor hormone Angiotensin II from binding, thereby directly inhibiting the activation of a key mediator within the body's pressor system at the molecular level.

By blocking the AT1 receptor, the drug engages the entire RAAS hormonal cascade, leading to two key physiological outcomes: vasodilation (widening of blood vessels) and a reduction in aldosterone release. This modification of a key regulatory pathway alters the systemic signaling patterns of Angiotensin II activity.

This mechanism leads to the physiological domain of vascular tone regulation, resulting in a decrease in systemic vascular resistance. This core effect contributes to a resulting adjustment in arterial blood pressure by reducing the force exerted on arterial walls.

Administration Guidelines

Кардосал 20 (Olmesartan Medoxomil) is a medication formulated as a film-coated tablet for oral administration only. Standard guidelines define a precise, once-daily regimen for its use in the management of high blood pressure.

---

Dosing and Administration Pattern

The standard protocol for use begins with a starting dose of 20 mg taken once a day. For adult patients who require further reduction in blood pressure after two weeks of treatment, the daily dosage may be increased to a maximum of 40 mg. Doses exceeding 40 mg once daily do not offer additional therapeutic benefit. The tablet should be swallowed whole with sufficient fluid and can be taken with or without food, providing flexibility for the long-term, sustained management of chronic hypertension.

---

Population-Specific Use and Adjustments

Administration guidelines for specific patient groups emphasize consistency and caution. No initial dosage adjustment is generally required for older adult patients or for those with moderate renal impairment. For patients who may be volume-depleted (e.g., those on high-dose diuretic therapy), consideration should be given to initiating therapy with a lower starting dose under close medical supervision. In the event that a dose is missed, the next dose should be taken at the regular scheduled time, without taking two doses at once to compensate.

---

Instruction Entity	Statement
Route of administration	Oral
Dosing schedule (Adults)	Starting Dose: 20 mg once daily. Max: 40 mg once daily
Timing in relation to meals	May be administered with or without food
Frequency pattern	Once daily (QD) for long-term maintenance
Special procedural conditions	Lower starting dose considered for volume-depleted patients

Research Evidence Overview

Кардосал 20 (Olmesartan medoxomil 20 mg) is an angiotensin II receptor blocker (ARB) studied for the management of high blood pressure (hypertension). The medication is a prodrug that is converted to the active compound, olmesartan, which acts by selectively blocking the AT1 receptor. This action is hypothesized to prevent the vasoconstricting effects of angiotensin II, contributing to blood pressure reduction.

Efficacy and Dosing Studies

Multiple randomized, double-blind trials have been conducted to evaluate the effects of olmesartan medoxomil in adults with hypertension. Pooled analyses of various studies indicated that 20 mg to 40 mg doses of olmesartan medoxomil were associated with significant reductions in both systolic blood pressure (SBP) and diastolic blood pressure (DBP) when compared to placebo.

• Onset of effect: Significant differences in blood pressure from placebo were observed starting as early as two weeks after treatment initiation in some trials.
• Dose comparisons: In several trials, olmesartan medoxomil 20 mg was found to be statistically associated with greater reductions in primary endpoints (such as mean change from baseline DBP) compared to recommended doses of certain other ARBs, including losartan and valsartan.

Safety Profile and Tolerability

In clinical studies involving olmesartan medoxomil as monotherapy, the occurrence of adverse events was generally similar to that reported in the placebo groups. Common adverse events in trials typically included dizziness and headache. Data from post-marketing surveillance and long-term open-label studies suggest a favorable tolerability profile. No clinically significant differences in effectiveness or safety were noted between elderly patients (ge 65 years) and younger adult patients, though greater sensitivity in some older individuals is always a possibility.

Common questions about Кардосал 20 (FAQ)

Q: Is Кардосал 20 used for high blood pressure only, or are there other common uses?

A: Official documents state that Кардосал 20 is indicated for the treatment of hypertension, which is high blood pressure. It is used to manage this condition long-term and may be prescribed alone or in combination with other agents that help lower blood pressure.

Q: How long does it typically take for Кардосал 20 to show its full effect on blood pressure?

A: The official product information indicates that while a substantial difference may be observed within the first two weeks, the maximum blood pressure-lowering effect is generally attained by about eight weeks after therapy is initiated. This timeframe reflects the sustained nature of the treatment.

Q: Is feeling dizzy or light-headed a frequent experience when starting Кардосал 20?

A: Official data indicates that dizziness is one of the most commonly reported side effects in clinical studies. Symptomatic low blood pressure, or hypotension, may be anticipated in volume-depleted patients, especially after the first dose.

Q: Can taking Кардосал 20 affect a person's kidney function over time?

A: Because the medication works on a system that regulates kidney function, periodic monitoring of blood markers such as serum creatinine and potassium levels is recommended, especially for people with existing kidney issues. This monitoring helps guide medical professionals and is generally not recommended for individuals with severe kidney impairment.

Q: Are there any specific dietary restrictions or concerns regarding salt substitutes while using Кардосал 20?

A: The regulatory profile notes a risk of hyperkalemia (elevated potassium levels). Because many salt substitutes contain potassium chloride, this concern extends to the concomitant use of salt substitutes and potassium supplements.

Q: Is it described in official documentation whether Кардосал 20 tablets can be divided or crushed?

A: The film-coated tablets are typically manufactured as non-scored, single units. The administration requirements described in the official documents specify that the tablets should be swallowed whole with fluid and not be split or divided.

Q: Has Кардосал 20 been the subject of long-term studies regarding its effects?

A: Yes, the risk-benefit profile for this medicine has been assessed in the context of the long-term management and outcomes of chronic hypertension in adults.

Q: Does official information suggest that dehydration can be a particular concern when taking Кардосал 20?

A: Official information highlights that conditions leading to volume or sodium depletion (dehydration) are a concern. This is because they can increase the possibility of symptomatic low blood pressure (hypotension). Regulatory guidance states that such underlying conditions should be corrected prior to use.

Q: How does the action of Кардосал 20 compare to ACE inhibitor medicines?

A: This medication belongs to a class called Angiotensin II Receptor Blockers (ARBs). It works by blocking the AT1 receptor directly. Unlike ACE Inhibitors (ACEi), which block the enzyme that creates the hormone Angiotensin II, this drug’s action is independent of that synthesis pathway.

Q: Is there an established link between Кардосал 20 use and the possibility of a persistent cough?

A: Unlike some older classes of blood pressure medication, the authoritative safety data for Кардосал 20 does not list persistent cough as a common or frequently reported adverse reaction.

Q: Does the consumption of alcohol interact with the effectiveness or safety of Кардосал 20?

A: Official regulatory information indicates that alcohol consumption may have an additive effect in lowering blood pressure. This combination can potentially increase the risk of symptoms like dizziness or lightheadedness due to the compounded blood pressure reduction.

Q: What is the difference between Кардосал 20 and the combination product Кардосал Плюс?

A: Кардосал 20 is a single-agent product containing only the active ingredient Olmesartan Medoxomil. Combination products, such as Кардосал Плюс, typically contain a second agent, often a diuretic (a 'water pill'), to provide an enhanced blood pressure-lowering effect.

Q: Why is it necessary to monitor blood pressure regularly while using Кардосал 20?

A: The fundamental goal of treatment is to use the blood pressure reduction to decrease the risk of serious cardiovascular events. Regular monitoring helps confirm that the desired effect is being achieved for the reduction of complications, such as strokes and heart attacks.

Q: What do clinical studies say about the ability of Кардосал 20 to protect against complications like stroke?

A: Regulatory information indicates that lowering high blood pressure with this medication is intended to reduce the risk of fatal and nonfatal cardiovascular events. This action is related to reducing the incidence of major complications, particularly strokes and myocardial infarctions (heart attacks).

Q: Are there potential issues when combining Кардосал 20 with certain medications for high cholesterol?

A: The official label notes a potential issue when combined with the cholesterol-lowering medication Colesevelam. The regulatory guidance indicates that Olmesartan is administered at least four hours before the Colesevelam dose to minimize the potential for interaction.

Q: What types of heart conditions, other than high blood pressure, might affect the use of Кардосал 20?

A: Official warnings indicate that special caution is necessary when the medication is used in patients with certain underlying heart conditions, such as severe congestive heart failure or ischemic heart disease. This is due to the possibility that an excessive drop in blood pressure could increase the risk of a serious cardiac event.

Q: Is it expected that I will need blood tests for kidney function while using Кардосал 20?

A: Periodic monitoring of blood levels, specifically serum potassium and creatinine (a marker of kidney function), is generally recommended when this medication is administered. This monitoring is particularly noted for patients who have existing issues with kidney function.

Q: What is the official guidance on managing vomiting or excessive sweating while on Кардосал 20?

A: The official guidance emphasizes that conditions causing significant fluid and sodium loss, such as severe vomiting or excessive sweating/diarrhea, must be corrected prior to use. This precaution is necessary because such conditions can lead to symptomatic low blood pressure (hypotension) when the medication is administered.

Q: Is there a link between the use of Кардосал 20 and hair loss, according to safety data?

A: While not common, authoritative post-marketing safety data indicates that alopecia, or hair loss, has been reported as a rare adverse event linked to this medication.

The storage and disposal of Кардосал 20 (Olmesartan Medoxomil) tablets must follow the specific instructions provided in the official regulatory labeling to maintain quality and safety.

Official Storage Conditions

Requirement	Specific Condition
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Environmental Protection	Keep away from heat, moisture, and direct light; must be kept from freezing.
Container	Store the medicine in a closed container.
Child Safety	Keep out of the reach of children.

Disposal Instructions

Unused or expired tablets should not be kept. The official regulatory instruction is to dispose of the unused product according to local requirements.

Consult a healthcare professional or follow local public service guidelines for proper pharmaceutical waste collection. Unless specifically instructed otherwise, the medicine should not be flushed down the toilet or poured into a drain.